axitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	4225	319460-85-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: axitinib inlyta AG 013736 AG-013736	A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA. Molecular weight: 386.47 Formula: C22H18N4OS CLOGP: 3.19 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 70.67 ALOGS: -5.85 ROTB: 5 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

axitinib
inlyta
AG 013736
AG-013736

A benzamide and indazole derivative that acts as a TYROSINE KINASE inhibitor of the VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR. It is used in the treatment of advanced RENAL CELL CARCINOMA.

Molecular weight: 386.47
Formula: C22H18N4OS
CLOGP: 3.19
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 70.67
ALOGS: -5.85
ROTB: 5

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
CL (Clearance)	5 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.30 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Jan. 27, 2012	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neoplasm progression	606.52	23.51	212	7838	36216	63444756
Diarrhoea	346.84	23.51	436	7614	714930	62766042
Disease progression	305.38	23.51	191	7859	122567	63358405
Death	291.56	23.51	293	7757	374088	63106884
Hypertension	223.10	23.51	222	7828	279081	63201891
Palmar-plantar erythrodysaesthesia syndrome	218.55	23.51	89	7961	22926	63458046
Dysphonia	181.69	23.51	98	7952	47516	63433456
Decreased appetite	149.53	23.51	171	7879	250881	63230091
Stomatitis	140.42	23.51	126	7924	138599	63342373
Blood pressure increased	134.85	23.51	132	7918	161930	63319042
Fatigue	123.21	23.51	314	7736	887714	62593258
Hypothyroidism	92.43	23.51	61	7989	42571	63438401
Oral pain	90.60	23.51	52	7998	28342	63452630
Drug ineffective	66.51	23.51	25	8025	1044740	62436232
Off label use	64.25	23.51	209	7841	674253	62806719
Dehydration	56.33	23.51	88	7962	173266	63307706
Nausea	56.32	23.51	235	7815	854236	62626736
Posterior reversible encephalopathy syndrome	50.64	23.51	30	8020	17315	63463657
Weight decreased	48.83	23.51	108	7942	276690	63204282
Proteinuria	42.94	23.51	28	8022	19117	63461855
Immune-mediated hepatic disorder	40.39	23.51	10	8040	505	63480467
Polycythaemia	39.20	23.51	11	8039	904	63480068
Asthenia	35.52	23.51	118	7932	383486	63097486
Constipation	33.30	23.51	82	7968	224861	63256111
Oligodipsia	30.14	23.51	5	8045	30	63480942
Drug hypersensitivity	28.75	23.51	3	8047	310684	63170288
Malignant neoplasm progression	27.05	23.51	42	8008	82079	63398893
Hyperkeratosis	24.63	23.51	13	8037	6005	63474967
Second primary malignancy	23.85	23.51	14	8036	7939	63473033

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neoplasm progression	1278.46	19.50	485	19457	22815	34914174
Dysphonia	1133.82	19.50	445	19497	22938	34914051
Disease progression	793.07	19.50	582	19360	107495	34829494
Diarrhoea	696.78	19.50	971	18971	388941	34548048
Hypertension	512.35	19.50	500	19442	135943	34801046
Fatigue	493.01	19.50	806	19136	369847	34567142
Death	461.11	19.50	814	19128	397235	34539754
Palmar-plantar erythrodysaesthesia syndrome	361.23	19.50	181	19761	16614	34920375
Decreased appetite	314.33	19.50	428	19514	165964	34771025
Blood pressure increased	268.22	19.50	289	19653	87813	34849176
Stomatitis	223.99	19.50	189	19753	42325	34894664
Oral pain	168.29	19.50	94	19848	10733	34926256
Hypothyroidism	164.68	19.50	118	19824	20784	34916205
Aphonia	151.85	19.50	61	19881	3312	34933677
Drug ineffective	141.29	19.50	43	19899	456708	34480281
Glossodynia	133.16	19.50	57	19885	3636	34933353
Weight decreased	108.08	19.50	280	19662	176021	34760968
Immune-mediated hepatic disorder	96.75	19.50	32	19910	991	34935998
Dry skin	76.86	19.50	92	19850	31195	34905794
Proteinuria	74.52	19.50	71	19871	18571	34918418
Blister	67.60	19.50	74	19868	22784	34914205
Dry mouth	66.50	19.50	84	19858	30081	34906908
Nausea	66.40	19.50	374	19568	339534	34597455
Pain in extremity	57.89	19.50	181	19761	126332	34810657
Febrile neutropenia	56.80	19.50	6	19936	136843	34800146
Thyroid disorder	55.98	19.50	30	19912	3152	34933837
Neutropenia	55.54	19.50	11	19931	156767	34780222
Blood pressure abnormal	55.33	19.50	42	19900	8064	34928925
Product dose omission in error	53.26	19.50	26	19916	2248	34934741
Second primary malignancy	51.93	19.50	40	19902	7846	34929143
Drug interaction	49.81	19.50	34	19908	225912	34711077
Constipation	49.44	19.50	181	19761	136801	34800188
Oral discomfort	49.43	19.50	26	19916	2631	34934358
Taste disorder	48.67	19.50	37	19905	7118	34929871
Off label use	48.08	19.50	405	19537	419119	34517870
Product dose omission issue	45.58	19.50	161	19781	119550	34817439
Asthenia	44.57	19.50	265	19677	244986	34692003
Toxicity to various agents	44.35	19.50	30	19912	200332	34736657
Overdose	40.45	19.50	3	19939	91056	34845933
Therapy interrupted	39.89	19.50	44	19898	13653	34923336
Pneumonia	39.05	19.50	94	19848	362533	34574456
Thrombocytopenia	36.47	19.50	22	19920	156225	34780764
Blood thyroid stimulating hormone increased	35.74	19.50	25	19917	4230	34932759
Adrenal insufficiency	35.62	19.50	42	19900	14005	34922984
Anaemia	35.32	19.50	49	19893	233286	34703703
Tongue discomfort	33.95	19.50	13	19929	620	34936369
Body surface area decreased	33.74	19.50	6	19936	8	34936981
Pancytopenia	33.00	19.50	7	19935	95150	34841839
Headache	31.53	19.50	209	19733	200426	34736563
Oropharyngeal pain	28.81	19.50	63	19879	35422	34901567
Skin exfoliation	28.57	19.50	54	19888	27378	34909611
Cardiac arrest	26.23	19.50	11	19931	96148	34840841
Rhabdomyolysis	25.82	19.50	4	19938	68159	34868830
Osteonecrosis of jaw	24.87	19.50	40	19902	17849	34919140
Dehydration	23.24	19.50	140	19802	129829	34807160
Protein urine present	22.98	19.50	21	19921	5207	34931782
Oral mucosal blistering	22.89	19.50	14	19928	1888	34935101
Hepatic function abnormal	22.61	19.50	66	19876	44297	34892692
Hyperkeratosis	22.49	19.50	18	19924	3731	34933258
Posterior reversible encephalopathy syndrome	22.37	19.50	28	19914	9926	34927063
Thyroid function test abnormal	22.30	19.50	10	19932	713	34936276
Multiple organ dysfunction syndrome	22.13	19.50	8	19934	76558	34860431
Nephrectomy	21.35	19.50	10	19932	788	34936201
Drug hypersensitivity	20.73	19.50	10	19932	80519	34856470
Abdominal discomfort	20.64	19.50	78	19864	59757	34877232
Pyrexia	20.59	19.50	109	19833	332904	34604085
Tremor	20.15	19.50	11	19931	82576	34854413
Illness	19.84	19.50	31	19911	13498	34923491
Abdominal pain upper	19.75	19.50	87	19855	71403	34865586
Hospice care	19.70	19.50	22	19920	6918	34930071

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neoplasm progression	1793.44	19.43	667	26058	51015	79666648
Dysphonia	1213.07	19.43	517	26208	56355	79661308
Disease progression	1012.68	19.43	677	26048	183685	79533978
Diarrhoea	954.36	19.43	1308	25417	879181	78838482
Death	821.85	19.43	975	25750	565539	79152124
Hypertension	635.46	19.43	661	26064	330331	79387332
Fatigue	572.69	19.43	1070	25655	928657	78789006
Palmar-plantar erythrodysaesthesia syndrome	546.96	19.43	252	26473	32882	79684781
Decreased appetite	463.91	19.43	571	26154	341847	79375816
Blood pressure increased	372.32	19.43	404	26321	210956	79506707
Stomatitis	276.61	19.43	291	26434	146466	79571197
Oral pain	236.71	19.43	142	26583	31656	79686007
Hypothyroidism	231.67	19.43	169	26556	52223	79665440
Drug ineffective	205.36	19.43	55	26670	1080858	78636805
Weight decreased	163.02	19.43	364	26361	354834	79362829
Immune-mediated hepatic disorder	146.26	19.43	43	26682	1551	79716112
Aphonia	144.13	19.43	70	26655	10242	79707421
Proteinuria	102.70	19.43	86	26639	32416	79685247
Dry skin	97.36	19.43	117	26608	67878	79649785
Off label use	91.08	19.43	566	26159	906649	78811014
Constipation	89.54	19.43	252	26473	282798	79434865
Asthenia	86.76	19.43	370	26355	511319	79206344
Nausea	83.17	19.43	576	26149	956620	78761043
Product dose omission issue	77.88	19.43	220	26505	247317	79470346
Blood pressure abnormal	72.71	19.43	54	26671	17115	79700548
Drug hypersensitivity	72.12	19.43	8	26717	298908	79418755
Second primary malignancy	69.59	19.43	49	26676	14301	79703362
Taste disorder	67.53	19.43	50	26675	15773	79701890
Dry mouth	67.05	19.43	112	26613	87907	79629756
Product dose omission in error	63.74	19.43	37	26688	7751	79709912
Dehydration	63.38	19.43	205	26520	247982	79469681
Thyroid disorder	58.99	19.43	44	26681	14035	79703628
Febrile neutropenia	58.82	19.43	5	26720	230994	79486669
Toxicity to various agents	56.26	19.43	36	26689	421504	79296159
Blood thyroid stimulating hormone increased	51.42	19.43	35	26690	9673	79707990
Adrenal insufficiency	50.90	19.43	55	26670	28432	79689231
Drug interaction	49.46	19.43	40	26685	415143	79302520
Oral discomfort	48.89	19.43	34	26691	9726	79707937
Pain in extremity	47.94	19.43	245	26480	364293	79353370
Hyperkeratosis	45.87	19.43	30	26695	7760	79709903
Skin exfoliation	45.86	19.43	73	26652	55027	79662636
Blister	45.42	19.43	114	26611	119362	79598301
Polycythaemia	42.80	19.43	19	26706	2265	79715398
Treatment failure	42.55	19.43	4	26721	170482	79547181
Hepatic function abnormal	41.62	19.43	82	26643	73025	79644638
Body surface area decreased	41.21	19.43	8	26717	43	79717620
Posterior reversible encephalopathy syndrome	40.54	19.43	47	26678	26234	79691429
Overdose	39.55	19.43	7	26718	184199	79533464
Joint swelling	39.38	19.43	24	26701	288622	79429041
Malignant neoplasm progression	38.98	19.43	117	26608	135873	79581790
Pancytopenia	38.56	19.43	5	26720	165740	79551923
Tongue discomfort	38.38	19.43	18	26707	2435	79715228
Neutropenia	37.77	19.43	25	26700	287685	79429978
Renal impairment	37.26	19.43	127	26598	157656	79560007
Arthropathy	35.37	19.43	8	26717	177103	79540560
Rheumatoid arthritis	35.07	19.43	13	26712	208457	79509206
Oral mucosal blistering	34.21	19.43	23	26702	6228	79711435
Hospice care	34.02	19.43	28	26697	10296	79707367
Pneumonia	33.24	19.43	112	26613	660134	79057529
Sinusitis	33.20	19.43	12	26713	195489	79522174
Thyroiditis	32.79	19.43	20	26705	4585	79713078
Renal cancer	31.86	19.43	29	26696	12197	79705466
Osteonecrosis of jaw	30.26	19.43	53	26672	43173	79674490
Hyperthyroidism	29.79	19.43	37	26688	22172	79695491
Nephrectomy	28.48	19.43	14	26711	2101	79715562
Wheezing	28.42	19.43	3	26722	116661	79601002
Protein urine present	28.36	19.43	25	26700	10087	79707576
Nephrotic syndrome	28.14	19.43	26	26699	11148	79706515
Cancer pain	27.99	19.43	19	26706	5226	79712437
Thrombocytopenia	27.48	19.43	29	26696	265230	79452433
Cardiac arrest	26.88	19.43	12	26713	172084	79545579
Feeding disorder	26.64	19.43	30	26695	16224	79701439
Condition aggravated	26.58	19.43	83	26642	501041	79216622
Renal cell carcinoma	26.32	19.43	20	26705	6558	79711105
Oligodipsia	25.43	19.43	5	26720	29	79717634
Asthma	25.23	19.43	7	26718	135088	79582575
Hypersensitivity	24.64	19.43	31	26694	262208	79455455
Hepatic cytolysis	24.02	19.43	37	26688	27114	79690549
Eating disorder	23.88	19.43	32	26693	20665	79696998
Agitation	23.20	19.43	3	26722	99712	79617951
Pemphigus	23.16	19.43	3	26722	99579	79618084
Bronchitis	22.21	19.43	8	26717	130636	79587027
Dysgeusia	22.18	19.43	55	26670	57122	79660541
Anaemia	22.01	19.43	76	26649	444939	79272724
Pyrexia	21.67	19.43	136	26589	678573	79039090
Immune-mediated renal disorder	21.25	19.43	6	26719	187	79717476
Ageusia	21.18	19.43	27	26698	16605	79701058
Blood corticotrophin increased	21.09	19.43	6	26719	192	79717471
Immune-mediated hypothyroidism	20.89	19.43	8	26717	655	79717008
Syncope	20.46	19.43	18	26707	179431	79538232
Weight increased	20.14	19.43	39	26686	277347	79440316
Oropharyngeal pain	19.93	19.43	81	26644	109272	79608391
Cardiac dysfunction	19.80	19.43	14	26711	4110	79713553
Immune-mediated myocarditis	19.72	19.43	9	26716	1144	79716519

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EK01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
FDA MoA	N0000020000	Receptor Tyrosine Kinase Inhibitors
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:38637	tyrosine kinase inhibitors
CHEBI has role	CHEBI:65207	vascular endothelial growth factor receptor inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal cell carcinoma	indication	702391001	DOID:4450

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.57	acidic
pKa2	12.18	acidic
pKa3	4.85	Basic
pKa4	1.98	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1MG	INLYTA	PF PRISM CV	N202324	Jan. 27, 2012	RX	TABLET	ORAL	10570202	Feb. 3, 2035	IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
5MG	INLYTA	PF PRISM CV	N202324	Jan. 27, 2012	RX	TABLET	ORAL	10570202	Feb. 3, 2035	IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
1MG	INLYTA	PF PRISM CV	N202324	Jan. 27, 2012	RX	TABLET	ORAL	10869924	Jan. 12, 2037	AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
5MG	INLYTA	PF PRISM CV	N202324	Jan. 27, 2012	RX	TABLET	ORAL	10869924	Jan. 12, 2037	AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Vascular endothelial growth factor receptor 3	Kinase	P35916	VGFR3_HUMAN	INHIBITOR	Kd	6.77	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 1	Kinase	P17948	VGFR1_HUMAN	INHIBITOR	Kd	8.24	CHEMBL	CHEMBL
Vascular endothelial growth factor receptor 2	Kinase	P35968	VGFR2_HUMAN	INHIBITOR	Kd	8.23	CHEMBL	CHEMBL
Mast/stem cell growth factor receptor Kit	Kinase	P10721	KIT_HUMAN		Kd	9.31	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		Kd	5.64	CHEMBL
Breakpoint cluster region protein	Kinase	P11274	BCR_HUMAN		Kd	6.73	CHEMBL
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		Kd	5.57	CHEMBL
Tyrosine-protein kinase Yes	Kinase	P07947	YES_HUMAN		Kd	5.57	CHEMBL
Receptor-type tyrosine-protein kinase FLT3	Kinase	P36888	FLT3_HUMAN		Kd	7.51	CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret	Kinase	P07949	RET_HUMAN		Kd	7	CHEMBL
Macrophage colony-stimulating factor 1 receptor	Kinase	P07333	CSF1R_HUMAN		Kd	7.68	CHEMBL
Platelet-derived growth factor receptor alpha	Kinase	P16234	PGFRA_HUMAN		Kd	9.29	CHEMBL
Mitogen-activated protein kinase 8	Kinase	P45983	MK08_HUMAN		Kd	5.41	CHEMBL
Fibroblast growth factor receptor 3	Kinase	P22607	FGFR3_HUMAN		Kd	6.68	CHEMBL
Mitogen-activated protein kinase 10	Kinase	P53779	MK10_HUMAN		Kd	5.96	CHEMBL
High affinity nerve growth factor receptor	Kinase	P04629	NTRK1_HUMAN		Kd	5.74	CHEMBL
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN		Kd	5.48	CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle	Kinase	Q9H1R3	MYLK2_HUMAN		Kd	5.89	CHEMBL
Tyrosine-protein kinase CSK	Kinase	P41240	CSK_HUMAN		Kd	5.96	CHEMBL
Angiopoietin-1 receptor	Kinase	Q02763	TIE2_HUMAN		Kd	6.51	CHEMBL
AP2-associated protein kinase 1	Kinase	Q2M2I8	AAK1_HUMAN		Kd	5.92	CHEMBL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN		Kd	6.09	CHEMBL
Fibroblast growth factor receptor 1	Kinase	P11362	FGFR1_HUMAN		Kd	6.42	CHEMBL
Serine/threonine-protein kinase 10	Kinase	O94804	STK10_HUMAN		Kd	5.92	CHEMBL
Serine/threonine-protein kinase PLK4	Kinase	O00444	PLK4_HUMAN		Ki	8.38	CHEMBL
Aurora kinase C	Kinase	Q9UQB9	AURKC_HUMAN		Kd	8.89	CHEMBL
Serine/threonine-protein kinase 16	Kinase	O75716	STK16_HUMAN		Kd	6.43	CHEMBL
Dual specificity protein kinase TTK	Kinase	P33981	TTK_HUMAN		Kd	5.41	CHEMBL
Abelson tyrosine-protein kinase 2	Kinase	P42684	ABL2_HUMAN		Kd	7.15	CHEMBL
Fibroblast growth factor receptor 2	Kinase	P21802	FGFR2_HUMAN		Kd	6.96	CHEMBL
TRAF2 and NCK-interacting protein kinase	Kinase	Q9UKE5	TNIK_HUMAN		Kd	6.74	CHEMBL
Tyrosine-protein kinase Fgr	Kinase	P09769	FGR_HUMAN		Kd	5.74	CHEMBL
Aurora kinase A	Kinase	O14965	AURKA_HUMAN		Kd	7.14	CHEMBL
BMP-2-inducible protein kinase	Kinase	Q9NSY1	BMP2K_HUMAN		Kd	6	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5	Kinase	Q9Y4K4	M4K5_HUMAN		Kd	6.26	CHEMBL
Mitogen-activated protein kinase kinase kinase 4	Kinase	Q9Y6R4	M3K4_HUMAN		Kd	5.25	CHEMBL
Cyclin-G-associated kinase	Kinase	O14976	GAK_HUMAN		Kd	5.57	CHEMBL
Receptor-interacting serine/threonine-protein kinase 2	Kinase	O43353	RIPK2_HUMAN		Kd	5	CHEMBL
Cyclin-dependent kinase 16	Kinase	Q00536	CDK16_HUMAN		Kd	5.28	CHEMBL
Serine/threonine-protein kinase 4	Kinase	Q13043	STK4_HUMAN		Kd	5.85	CHEMBL
Activated CDC42 kinase 1	Kinase	Q07912	ACK1_HUMAN		Kd	5.22	CHEMBL
STE20-like serine/threonine-protein kinase	Kinase	Q9H2G2	SLK_HUMAN		Kd	6	CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2	Kinase	Q96RR4	KKCC2_HUMAN		Kd	5.82	CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1	Kinase	Q8N5S9	KKCC1_HUMAN		Kd	5.85	CHEMBL
Epithelial discoidin domain-containing receptor 1	Kinase	Q08345	DDR1_HUMAN		Kd	6.47	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1	Kinase	Q02750	MP2K1_HUMAN		Kd	5.57	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2	Kinase	P36507	MP2K2_HUMAN		Kd	5.59	CHEMBL
Tyrosine-protein kinase ITK/TSK	Kinase	Q08881	ITK_HUMAN		Kd	5.92	CHEMBL
Tyrosine-protein kinase receptor UFO	Kinase	P30530	UFO_HUMAN		Kd	6.38	CHEMBL
Serine/threonine-protein kinase N2	Kinase	Q16513	PKN2_HUMAN		Kd	5.57	CHEMBL
Serine/threonine-protein kinase 3	Kinase	Q13188	STK3_HUMAN		Kd	5.66	CHEMBL
NUAK family SNF1-like kinase 2	Kinase	Q9H093	NUAK2_HUMAN		Kd	5.89	CHEMBL
Non-receptor tyrosine-protein kinase TNK1	Kinase	Q13470	TNK1_HUMAN		Kd	6.80	CHEMBL
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN		Kd	5.44	CHEMBL
Mitogen-activated protein kinase kinase kinase MLT	Kinase	Q9NYL2	MLTK_HUMAN		Kd	5.59	CHEMBL
Serine/threonine-protein kinase RIO1	Kinase	Q9BRS2	RIOK1_HUMAN		Kd	5.92	CHEMBL
Tyrosine-protein kinase receptor Tie-1	Kinase	P35590	TIE1_HUMAN		Kd	7.01	CHEMBL
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN		Kd	5.62	CHEMBL
Casein kinase II subunit alpha'	Kinase	P19784	CSK22_HUMAN		Kd	5.55	CHEMBL
Serine/threonine-protein kinase RIO3	Kinase	O14730	RIOK3_HUMAN		Kd	6	CHEMBL
SRSF protein kinase 1	Kinase	Q96SB4	SRPK1_HUMAN		Kd	5.74	CHEMBL
Activin receptor type-2B	Kinase	Q13705	AVR2B_HUMAN		Kd	5.28	CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1	Kinase	Q8NFD2	ANKK1_HUMAN		Kd	5.44	CHEMBL
Discoidin domain-containing receptor 2	Kinase	Q16832	DDR2_HUMAN		Kd	5.28	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1	Kinase	Q92918	M4K1_HUMAN		Kd	6.48	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3	Kinase	Q8IVH8	M4K3_HUMAN		Kd	5.92	CHEMBL
Aurora kinase B	Kinase	Q96GD4	AURKB_HUMAN		Kd	7.96	CHEMBL
Tyrosine-protein kinase Blk	Kinase	P51451	BLK_HUMAN		Kd	5.51	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4	Kinase	O95819	M4K4_HUMAN		Kd	6.46	CHEMBL
Tyrosine-protein kinase Mer	Kinase	Q12866	MERTK_HUMAN		Kd	5.49	CHEMBL
Mitogen-activated protein kinase kinase kinase 9	Kinase	P80192	M3K9_HUMAN		Kd	5.52	CHEMBL
Serine/threonine-protein kinase MRCK beta	Kinase	Q9Y5S2	MRCKB_HUMAN		Kd	5.32	CHEMBL
Myosin-IIIa	Kinase	Q8NEV4	MYO3A_HUMAN		Kd	5.72	CHEMBL
Serine/threonine-protein kinase PAK 4	Kinase	O96013	PAK4_HUMAN		Kd	5.35	CHEMBL
Serine/threonine-protein kinase SIK1	Kinase	P57059	SIK1_HUMAN		Kd	5.68	CHEMBL
Dual specificity testis-specific protein kinase 1	Kinase	Q15569	TESK1_HUMAN		Kd	5.37	CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase	Kinase	P19525	E2AK2_HUMAN		Kd	5.13	CHEMBL
Receptor-interacting serine/threonine-protein kinase 1	Kinase	Q13546	RIPK1_HUMAN		Kd	5.60	CHEMBL
Proto-oncogene tyrosine-protein kinase ROS	Kinase	P08922	ROS1_HUMAN		Kd	5.49	CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2	Kinase	Q12851	M4K2_HUMAN		Kd	5.89	CHEMBL
Misshapen-like kinase 1	Kinase	Q8N4C8	MINK1_HUMAN		Kd	6.25	CHEMBL
Cyclin-dependent kinase-like 2	Kinase	Q92772	CDKL2_HUMAN		Kd	6.28	CHEMBL
Ephrin type-B receptor 6	Kinase	O15197	EPHB6_HUMAN		Kd	6.44	CHEMBL
G protein-coupled receptor kinase 4	Kinase	P32298	GRK4_HUMAN		Kd	5.64	CHEMBL
Hormonally up-regulated neu tumor-associated kinase	Kinase	P57058	HUNK_HUMAN		Kd	5.82	CHEMBL
Interleukin-1 receptor-associated kinase 1	Kinase	P51617	IRAK1_HUMAN		Kd	5.51	CHEMBL
Mitogen-activated protein kinase kinase kinase 3	Kinase	Q99759	M3K3_HUMAN		Kd	5.55	CHEMBL
SRSF protein kinase 3	Kinase	Q9UPE1	SRPK3_HUMAN		Kd	5.64	CHEMBL
Serine/threonine-protein kinase ULK2	Kinase	Q8IYT8	ULK2_HUMAN		Kd	5	CHEMBL
Serine/threonine-protein kinase ULK3	Kinase	Q6PHR2	ULK3_HUMAN		Kd	6.17	CHEMBL
Mitogen-activated protein kinase kinase kinase 19	Kinase	Q56UN5	M3K19_HUMAN		Kd	6.57	CHEMBL
Receptor-interacting serine/threonine-protein kinase 4	Kinase	P57078	RIPK4_HUMAN		Kd	5.85	CHEMBL
Bone morphogenetic protein receptor type-1B	Kinase	O00238	BMR1B_HUMAN		Kd	5.54	CHEMBL
Mitogen-activated protein kinase kinase kinase 12	Kinase	Q12852	M3K12_HUMAN		Kd	5.77	CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5	Kinase	Q13163	MP2K5_HUMAN		Kd	6.85	CHEMBL
Myosin light chain kinase 3	Kinase	Q32MK0	MYLK3_HUMAN		Kd	5.77	CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2	Kinase	Q5S007	LRRK2_HUMAN		Kd	6.04	CHEMBL
Ferrochelatase, mitochondrial	Enzyme	P22830	HEMH_HUMAN		Kd	5.17	CHEMBL
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN		Kd	5.51	CHEMBL
Uncharacterized protein FLJ45252	Unclassified	Q6ZSR9	YJ005_HUMAN		Kd	5.64	CHEMBL
Platelet-derived growth factor receptor beta	Kinase	P09619	PGFRB_HUMAN		Kd	9.24	CHEMBL
Tyrosine-protein kinase ABL1	Kinase	P00519	ABL1_HUMAN		Kd	8.82	CHEMBL

External reference:

ID	Source
4031332	VUID
N0000184323	NUI
D03218	KEGG_DRUG
4031332	VANDF
C1700874	UMLSCUI
CHEBI:66910	CHEBI
AXI	PDB_CHEM_ID
CHEMBL1289926	ChEMBL_ID
D000077784	MESH_DESCRIPTOR_UI
DB06626	DRUGBANK_ID
5659	IUPHAR_LIGAND_ID
8720	INN_ID
C9LVQ0YUXG	UNII
6450551	PUBCHEM_CID
1242999	RXNORM
187097	MMSL
28294	MMSL
d07823	MMSL
014143	NDDF
427882000	SNOMEDCT_US
429507005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0145	TABLET, FILM COATED	1 mg	ORAL	NDA	32 sections
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0145	TABLET, FILM COATED	1 mg	ORAL	NDA	32 sections
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0151	TABLET, FILM COATED	5 mg	ORAL	NDA	32 sections
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	0069-0151	TABLET, FILM COATED	5 mg	ORAL	NDA	32 sections
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	63539-026	TABLET, FILM COATED	1 mg	ORAL	NDA	32 sections
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	63539-026	TABLET, FILM COATED	1 mg	ORAL	NDA	32 sections
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	63539-044	TABLET, FILM COATED	5 mg	ORAL	NDA	32 sections
INLYTA	HUMAN PRESCRIPTION DRUG LABEL	1	63539-044	TABLET, FILM COATED	5 mg	ORAL	NDA	32 sections